Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses

Overview of attention for article published in BMC Neurology, October 2015

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
Good Attention Score compared to outputs of the same age and source (72nd percentile)

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 6,301 followers.

Quant. benefit–risk assessment of methylprednisolone in MS relapses https://t.co/Wutp30czi9

RT @UMCGlobalSafety: Read "Quant. beneft—risk assessmnt of methylprednisolone in #MS relapses" by @OlaCaster & Edwards in @BioMedCentral: h…

Read "Quant. beneft—risk assessmnt of methylprednisolone in #MS relapses" by @OlaCaster & Edwards in @BioMedCentral: https://t.co/urKio3TXKK

Read @OlaCaster &; Edward's "Quantitative benefit-risk asst of #methylprednisolone in #MS relapses" in #BMCNeurology: https://t.co/NDOYQDt0Ib

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.